Atopic Dermatitis

Todd Schlesinger, MD, talks new therapies on the horizon and those that have already proven efficacious.

Peter Lio, MD talks about the promise and risks of cannabinoids as potential treatment for itch.

Peter Lio, MD, discusses the various underlying causes behind itch.

In this episode of Derm Discussions, Peter Lio, MD, discusses the difficulties treating itch as well as alternative—and perhaps surprising—therapeutic options.

The FDA approvals of biologics for atopic dermatitis and psoriasis have ushered in a new era for the once-stagnant field of pediatric dermatology.

In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.

A pediatric dermatologist discusses dupilumab for pediatric atopic dermatitis in addition to promising new therapies.

Lisa Swanson, MD, and Brad Glick, DO, FAAD, discuss a wide range of dermatological conditions faced by pediatric patients—from acne to atopic dermatitis, and everything in between.

Brad Glick gives an overview of new and exciting trends in the field of dermatology.

FDA application is based on the positive data from 3 recent phase 3 clinical trials.

Though atopic dermatitis is a relatively common condition, most of the existing scientific literature has ignored the majority of patients who have mild or limited disease.